Faes Farma, S.A. (BME:FAE)
Spain
· Delayed Price · Currency is EUR 4.495
-0.005 (-0.11%)
Jun 27, 2025, 9:43 AM CET
Faes Farma Revenue
Faes Farma had revenue of 153.00M EUR in the quarter ending March 31, 2025, with 10.05% growth. This brings the company's revenue in the last twelve months to 524.02M, up 8.70% year-over-year. In the year 2024, Faes Farma had annual revenue of 510.04M with 7.81% growth.
Revenue (ttm)
524.02M
Revenue Growth
+8.70%
P/S Ratio
2.67
Revenue / Employee
295.22K
Employees
1,775
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 510.04M | 36.95M | 7.81% |
| Dec 31, 2023 | 473.09M | 11.38M | 2.46% |
| Dec 31, 2022 | 461.72M | 33.08M | 7.72% |
| Dec 31, 2021 | 428.64M | 17.15M | 4.17% |
| Dec 31, 2020 | 411.49M | 28.30M | 7.39% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.37B |
| Laboratorios Farmaceuticos Rovi | 767.47M |
| Almirall | 1.03B |
| Pharma Mar | 175.75M |
| Clínica Baviera | 279.53M |
| Laboratorio Reig Jofre | 340.41M |
| Oryzon Genomics | 7.36M |
| Prim, S.A. | 233.36M |